Copyright ©The Histochemical Society, Inc.

Biochemical and Histochemical Evidence of Nonspecific Binding of {alpha}7nAChR Antibodies to Mouse Brain Tissue

Donna L. Herber, Emily G. Severance, Javier Cuevas, Dave Morgan and Marcia N. Gordon

Alzheimer Research Laboratory, Department of Pharmacology and Therapeutics, University of South Florida, Tampa, Florida

Correspondence to: Marcia N. Gordon, University of South Florida, 12901 Bruce B. Downs Blvd., MDC Box 9, Tampa, FL 33612-4799. E-mail: mgordon{at}hsc.usf.edu


    Summary
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Alpha 7 nicotinic acetylcholine receptors are involved in learning and memory, and are implicated in the pathology of Alzheimer's disease and schizophrenia. Detection of {alpha}7 subunits can be accomplished via immunodetection or {alpha}-bungarotoxin-binding techniques. Standard protocols for immunohistochemistry and Western blotting were followed using several commercially available antibodies. Various mice were evaluated, including non-transgenics, APP, PS1, APP+PS1, and {alpha}7 knockouts. Initial results with amyloid-depositing mice revealed {alpha}7 immunolabeled astrocytes, in addition to expected neuronal staining. Subsequent studies with intrahippocampal injections of lipopolysaccharide (LPS) into {alpha}7 knockout mice showed that both neuronal and astrocytic labeling by {alpha}7 antibodies was nonspecific. On Western blots of mouse brain proteins, none of the bands detected with antibodies directed against {alpha}7 subunits diminished in the {alpha}7 knockout mice. Although LPS-related changes in the expression of some bands were found, these also were unaffected by the {alpha}7 genotype of the mice. In general, the Western staining patterns for these antibodies revealed few overlapping bands. These immunodetection data are in contrast to genotyping results and mRNA analyses that confirmed the disruption of the {alpha}7 allele and lack of {alpha}7 message in the knockouts. These findings suggest caution in interpreting results when using several commercially available {alpha}7 nicotinic receptor antibodies.

(J Histochem Cytochem 52:13671375, 2004)

Key Words: transgenic • lipopolysaccharide • alpha 7 nicotinic receptor • astrocytes • immunohistochemistry • Western blot


    Introduction
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
CHOLINERGIC DYSFUNCTION is a hallmark of Alzheimer's disease (AD) neurodegeneration. Specifically, the basal forebrain cholinergic system is affected with overall loss of nicotinic receptors, as well as decreased acetylcholine release and choline acetyltransferase activity (Auld et al. 2002Go). In vertebrates, the two main nicotinic acetylcholine receptors (nAChRs) in the brain are {alpha}4ß2 and {alpha}7, with smaller populations of {alpha}2-10 and ß3-4. Alpha 7 is a ligand-gated ion channel consisting of five identical subunits, has a high relative calcium permeability, and is distinguishable from other central nervous system nAChRs by its affinity for {alpha}-bungarotoxin (Seguela et al. 1993Go; McGehee and Role, 1995Go).

In human AD brain, nicotinic receptor populations have been extensively studied. Alpha 7 levels are generally decreased in AD, although there are variations in reports (reviewed in Perry et al. 2001Go). Declines in receptors may be due to cell loss or synaptic decline. Age-related changes in {alpha}7 expression in mice transgenic for a human mutated amyloid precursor protein (APP) have also been reported (Dineley et al. 2001Go,2002Go). Particular focus has been on {alpha}7 because of the potential interaction of the receptor with Aß peptides. Co-immunoprecipitation and receptor-binding assays indicate that Aß1-42 binds {alpha}7 with high affinity, but not {alpha}4ß2, in both human and rat tissue (Wang et al. 2000aGo,bGo). Studies conducted with wild-type {alpha}7 receptors indicate that Aß1-42 blocks the receptor (Liu et al. 2001Go; Pettit et al. 2001Go; Grassi et al. 2003Go; Lee and Wang 2003Go). Glial cells may also be involved in these interactions; recent reports have shown expression of {alpha}7 by reactive astrocytes in human AD brain, particularly in association with amyloid deposits (Wevers et al. 1999Go; Graham et al. 2002Go; Teaktong et al. 2003Go).

In these experiments, we used standard protocols for immunohistochemical and Western blot analysis of {alpha}7 nAChR subunits in murine models of AD and neuroinflammation. Several commercially available antibodies were evaluated, and the results compared with genotyping and RNA analyses. Initially, four genotypes resulting from breeding transgenic mice carrying either mutant APP or mutant presenilin 1 (PS1) were examined for {alpha}7 expression. Various reports in the literature led us to expect decreases in levels of nicotinic receptors in amyloid-depositing mice, such as the APP and APP+PS1 transgenics. Although no decreases in neuronal staining were seen, a surprising finding was {alpha}7-immunopositive astroglia in apposition with compact plaques in APP and APP+PS1 mice, but in not PS1 or non-transgenics. To determine if amyloid was causing the astrocytic {alpha}7 expression, or if it was part of a more general inflammatory response, we injected lipopolysaccharide (LPS) intrahippocampally into APP and non-transgenic mice. Immunohistochemical analysis revealed many {alpha}7-positive astrocytes in the injected animals, leading us to believe that the expression was part of a general inflammatory response. In a final experiment using {alpha}7-null mice, the specificity of the antibodies was tested under both control and LPS-stimulated conditions. No discernible differences were seen between {alpha}7+/+ versus {alpha}7–/– mice with any antibody used, regardless of the procedure. Genotyping and RNA analyses confirmed the disruption of the {alpha}7 allele and lack of {alpha}7 message in the knockouts. We therefore conclude that commercially available antibodies against {alpha}7 as used in the methods detailed here fail to specifically detect the subunits.


    Materials and Methods
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Mouse Strains
Transgenic mice were bred to develop Alzheimer's-like pathology using Tg2576 APP mice and line 5.1 PS1 mice, yielding four genotypes: non-transgenic, PS1, APP, and APP+PS1 transgenic (Holcomb et al. 1998Go). Alpha 7–null mutant mice, originally described by Orr-Urterger et al. in 1997, were derived from heterozygous breedings of animals purchased from Jackson Laboratories (Bar Harbor, ME). Non-transgenic and homozygous null mice from this cross were used in this study. Animals were group-housed under a 12 hr light–dark cycle with free access to chow and water. Experimental groups were balanced with regard to age and sex.

Genotyping
APP and PS1 lines were analyzed as previously reported (Gordon et al. 2001Go). Mice from the {alpha}7-null mutation line were genotyped as follows: 2-mm diameter ear clips from the {alpha}7 heterozygous breedings were digested and the DNA extracted using Qiagen's DNeasy Kit (Valencia, CA) according to the manufacturer's instructions. Jackson Laboratories supplied the sequence of primers used to identify either the neo-cassette of the null mutation or the wild-type allele, for use with the polymerase chain reaction (PCR): forward, 5'-CCTGGTCCTGCTGTGTTAAACTGCTTC-3'; reverse WT ({alpha}7+), 5'-CTGCTGGGAAATCCTAGGCACACTTGAG-3'; reverse Neo ({alpha}7), 5'-GACAAGACCGGCTTCCATCC-3'. Thermocycling conditions were as follows: 95C for 4 min; 30 cycles of 95C for 15 sec, 60C for 60 sec, 72C for 60 sec; 72C for 7.5 min; store at 4C. PCR products were run on a 1% agarose gel, using ethidium bromide ultraviolet (UV) detection of bands at 440 bp ({alpha}7+) or 750 bp ({alpha}7).

Intrahippocampal Injections
APP mice aged 16 months, {alpha}7-null mice aged 11 months, and their non-transgenic littermates were used in these studies. Mice were anesthetized using isoflurane and immobilized in a stereotaxic apparatus. One-µl injections of either saline or 4 µg/µl LPS (Salmonella abortus equi, Sigma, St Louis, MO) were delivered over a 2-min period into the hippocampus (stereotaxic coordinates from bregma: –2.7 mm posterior; ±2.5 mm lateral; –3.0 mm ventral). This procedure had been previously demonstrated in our lab to induce a neuroinflammatory response without adversely affecting animal survival (DiCarlo et al. 2001Go). All animal work was conducted under National Institutes of Health guidelines and approved by the University of South Florida's institutional animal care and use committee. Animals were singly housed for the seven-day posttreatment survival period under standard vivarium conditions.

Tissue Preparation
Mice were anesthetized with pentobarbital (200 mg/kg IP), then perfused transcardially with 25 ml of saline. The brain was removed, the right hemisphere dissected into regions, and the tissue stored at –80C for subsequent biochemical analyses. For immunohistochemistry, left hemispheres were transferred into a 4% paraformaldehyde solution for 24 hr, then processed through a cryprotection schedule of 10%, 20%, then 30% sucrose (24 hr in each solution). The tissue was sectioned horizontally on a sliding microtome at 25 µm. Sections were then stored in Dulbecco's phosphate-buffered saline (DPBS), pH 7.4, with sodium azide (100 mM) at 4C.

RNA Analysis
Mice obtained from the {alpha}7-heterozygous breedings were analyzed for mRNA using reverse transcription followed by PCR. The procedure was originally described in detail elsewhere (Dickey et al. 2003Go). RNA was extracted from the injected hippocampus of {alpha}7+ and {alpha}7 mice, using Qiagen's RNeasy procedure. RNA concentration was determined with Molecular Probes RiboGreen RNA quantitation kit (Molecular Probes, Eugene, OR). Reverse transcription with mMLV (Invitrogen, Carlsbad, CA) was performed, and the resulting cDNA subjected to PCR. Primers used to identify {alpha}7 were directed toward portions of exons 9–10: forward, 5'-GTGGGCCTCTCAGTGGTCGT-3'; reverse, 5'-GTCCCCATCAGAGGGGTGTG-3'. Thermocycling conditions were as follows: 95C for 3 min; 45 cycles of 95C for 15 sec, 60C for 60 sec, 72C for 60 sec; 72C for 7.5 min; store at 4C. PCR products were run on a 1% agarose gel, using ethidium bromide UV detection of bands at 381 bp.

Histology
Immunohistochemical analysis of {alpha}7 nAChRs was performed using 25-µm free-floating sections spaced 300 µm apart through the hippocampus. Details of this procedure were originally described elsewhere (Gordon et al. 1997Go). All steps were performed on a rotating platform at ~40 rpm, room temperature, unless otherwise stated. Sections were first blocked for endogenous peroxidases (10% methanol, 3% hydrogen peroxide in DPBS) for 15 min, then washed three times for 5 min with DPBS. The tissue was then permeabilized in a solution of 100 mM lysine, 0.2% Triton X-100, and 4% normal goat or horse serum (Pel Freeze, Rogers, AK) in DPBS for 30 min. Sections were then incubated overnight in the appropriate primary antibody in DPBS and 4% serum, without shaking (Table 1). The following day, sections were incubated with shaking in primary antibody for 1 hr, washed three times for 5 min with DPBS, and then incubated in the appropriate biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) at a concentration of 0.5 µg/ml in DPBS and 4% serum, for 2 hr. Sections were then washed three times for 5 min with DPBS, then incubated for 1 hr in Vectastain Elite ABC solution (Vector Laboratories) using 8 drops each of components A and B per 100 ml of DPBS. Sections were then washed two times for 5 min with DPBS, followed by a single wash in Tris-buffered saline (TBS), pH 7.6, for 5 min. The tissue was then incubated with a solution of 0.5% nickelous ammonium sulfate hexahydrate and 0.05% diaminobenzidine in TBS for 5 min. Color development was achieved by the addition of 0.03% hydrogen peroxide, and incubation for an additional 5 min, followed by a single wash in TBS, then two washes in DPBS, each for 5 min. Controls for nonspecific binding of the secondary antibody were performed by excluding primary antibodies. Stained sections were mounted onto slides and air dried overnight. Slides were then processed through a dehydration schedule of 10 dips in water, followed by two washes for 3 min each in 25%, 50%, and 75% ethanol, then three washes for 5 min each in 95% ethanol, 100% ethanol, and Histo-Clear (National Diagnostics, Atlanta, GA). Slides were coverslipped with DPX (E.M. Sciences, Fort Washington, PA) and allowed to dry overnight.


View this table:
[in this window]
[in a new window]
 
Table 1

Primary antibodies used for immunodetection

 
In some cases, tissue stained with {alpha}7 antibodies was counterstained with Congo red to verify the location of compact amyloid deposits. For this counterstain, immunostained sections were slide mounted and allowed to dry overnight. The slides were then hydrated for 30 sec in water. Slides were then submerged for 20 min in a solution of 80% ethanol saturated with sodium chloride, then made alkaline with a final concentration of 0.01% sodium hydroxide. Slides were then incubated for 30 min in a separate portion of alkaline alcoholic saturated sodium chloride containing 0.2% Congo red dye (solution filtered prior to use). Slides were then dehydrated with eight dips in 95% ethanol, then eight dips in two baths of 100% alcohol. The tissue was finally run through xylene three times for 5 min and coverslipped with DPX.

Western Blotting
Mice obtained from the {alpha}7-heterozygous breedings were analyzed for protein using SDS-PAGE followed by Western blot. Cerebral cortex previously stored at –80C was homogenized in 10 mM HEPES buffer, pH 7.4, containing a protease inhibitor cocktail (Roche, Indianapolis, IN). Crude protein concentrations were determined by the Bradford method using Bio-Rad Protein Assay Dye Reagent (Hercules, CA). Samples were denatured with Bio-Rad Laemmli sample buffer by boiling for 5 min. Ten µg of protein was loaded per well, and proteins were separated using 10% polyacrylamide Bio-Rad Ready Gels. Bio-Rad Precision-Plus Protein All Blue molecular weight standards were run for band identification. The separated proteins were transferred to Immobilon-P polyvinylidine fluoride membranes and immunoblotted (Millipore, Bedford, MA). Membranes were first blocked with 5% non-fat dry milk in borate-buffered saline, pH 8.5, and 0.05% Tween-20 (BST) for 1 hr on a rocking platform at room temperature. Membranes were then incubated with primary antibody in 2.5% non-fat dry milk in BST for one hour (Table 1). After washing three times for 5 min with BST, blots were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) at a 1:10,000 dilution in 2.5% milk-BST for 30 min. Finally, membranes were triple washed in BST. Bands were identified using Western Blotting Luminol Reagent (Santa Cruz Biotechnology) for chemiluminescent detection and subsequent film exposure for 0.5–5 min. The presence of {alpha}7 protein was verified by comparing the protein bands to the molecular weight standard markers. The expected molecular weight of the {alpha}7 subunit was 56 kDa.


    Results
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Standard protocols for immunohistochemical and Western blot detection of {alpha}7 nAChR subunits were followed using several commercially available antibodies. These results were ultimately compared with genotyping and mRNA analyses of the {alpha}7 subunit. Initially, four genotypes resulting from breeding of APP and PS1 transgenics were examined for {alpha}7 expression. Previous data had been published demonstrating the amyloid burden, gliosis, and behavioral phenotype of these mice (Gordon et al. 2002Go). The antibodies used for the current study included a rat monoclonal antibody (mAb 319), a mouse monoclonal (mAB 306), and a rabbit polyclonal (pAb H-302). In non-transgenic mice (Figure 1) , distinct ubiquitous positive immunostaining was seen throughout the brain with mAb 319. Regions analyzed included the dentate gyrus of the hippocampus, frontal cortex, striatum, and cerebellum. These results are consistent with previous reports (Del Toro et al. 1994Go).



View larger version (58K):
[in this window]
[in a new window]
 
Figure 1

Immunolabeling by {alpha}7 antibodies in non-transgenic mouse brain. Horizontal sections were immunostained using mAb 319 at a 1:5000 dilution. Ubiquitous neuronal stain was seen in all regions examined, including the dentate gyrus of the hippocampus (A), cerebral cortex (B), striatum (C), and cerebellum (D). Bar = 100 µm.

 
Mice transgenic for APP+PS1 were next analyzed. Distinct neuronal staining was noted with mAb 319 (not shown), similar to that seen in non-transgenics (Figure 1). A comparison of non-transgenic versus APP+PS1 mice revealed no differences in the intensity of neuronal staining in any region. In amyloid-bearing regions, such as the hippocampus and cortex, immunolabeling of reactive astrocytes was also noted. The cells were deemed astrocytes on the basis of their size, morphology, and distribution within the laminated regions, such as hippocampus. The {alpha}7-immunopositive astrocytes seemed to cluster around amyloid deposits. This clustering was confirmed when brain sections were counter-stained with Congo red (Figure 2) . This micrograph shows mAb 319–positive cells associated with a congophillic plaque. APP mice showed similar patterns of astrocytic staining, but to a lesser degree, possibly because of the lower amyloid burden in these mice (data not shown). PS1 mice resembled non-transgenics; rarely were {alpha}7-immunolabeled astrocytes seen in those mice.



View larger version (144K):
[in this window]
[in a new window]
 
Figure 2

Reactive astrocytes colocalize with congophillic plaques in APP+PS1 mice. Horizontal sections were immunostained using mAb 319 at a 1:5000 dilution and then counterstained with Congo red. Micrographs show the molecular layer of the CA3 region of the hippocampus. Black staining of the cell bodies is clearly defined, with faint staining of processes, all surrounding the red plaque core. Bar = 50 µm.

 
To determine whether {alpha}7 expression by reactive astrocytes was due to a generalized inflammatory response to amyloid, we injected LPS into the right hippocampus of APP and non-transgenic mice. LPS treatment resulted in a widespread pattern of mAb 319 immunolabeling of astrocytes, cells known to react to LPS injections (Hauss-Wegrzyniak et al. 1998Go). No changes were seen in neuronal staining with mAb 319 (Figure 3) . Figure 3 depicts the CA3 regions of saline-injected (panels A,C) versus LPS-injected mice (panels B,D). A few immunopositive astrocytes were seen in saline-treated APP mice (panel C), but not in the non-transgenics (panel A). All mice showed reactive {alpha}7-immunopositive astrocytes upon LPS treatment (panels B,D).



View larger version (54K):
[in this window]
[in a new window]
 
Figure 3

Lipopolysaccharide (LPS) stimulates astrogliosis and immunolabeling by anti-{alpha}7 antibodies. Non-transgenic (A,B) and APP (C,D) mice were injected with saline (A,C) or LPS (B,D) 7 days prior to sacrifice. Horizontal sections were immunostained using mAb 319 at a 1:5000 dilution. Micrographs show the CA3 region of the injected hippocampus. Pyramidal cells were intensely stained, located in the upper left corner of each panel. LPS treatment resulted in widespread activation of astrocytes, which were immunolabeled by mAb 319 (B,D). Bar = 50 µm.

 
In a final set of experiments, LPS was injected into {alpha}7-null mice, thus testing the specificity of the anti-{alpha}7 antibodies. Mice carrying a null deletion for {alpha}7 were genotyped and selected to be either non-transgenic ({alpha}7+) or homozygous null ({alpha}7). Genotyping results indicated a single band at 440 bp for {alpha}7+ mice or at 750 bp for {alpha}7-null mice. Figure 4A shows typical PCR product banding for non-transgenic and null genotypes. All mice were genotyped and sorted on the basis of these results. Subsequently, RNA was extracted from the hippocampus, reverse transcribed, and subjected to PCR to determine whether {alpha}7 mRNA was expressed. Mice that had been genotyped as {alpha}7 did not express {alpha}7 mRNA. Typical samples are shown in Figure 4B, with a positive signal at 381 bp in lane 1 (non-transgenic), as well as a smaller primer-dimer product running at the end of the gel (present even in the absence of cDNA). All animals genotypically {alpha}7+ also had {alpha}7 mRNA; none of the {alpha}7-null mutant mice had {alpha}7 mRNA.



View larger version (35K):
[in this window]
[in a new window]
 
Figure 4

Genotyping and RNA analysis of {alpha}7+ and {alpha}7 mice. (A) A typical PCR product with ethidium bromide/UV detection of genomic DNA. Lanes 1 and 2 are from an {alpha}7+ mouse, showing only a 440 bp band in lane 1 indicating the wild-type allele, but no band for the neo-cassette primers in lane 2. Lanes 3 and 4 are from a homozygous null mutant {alpha}7 mouse and lack the band for the wild-type primers in lane 3, showing only a 750 bp band indicating the neo-cassette disrupted allele in lane 4. (B) A typical RT-PCR product derived from mRNA and detected with ethidium bromide/UV. Both lanes show a small product due to primer-dimer formation. Lane 1 shows a single specific band of the expected size of 381 bp from an {alpha}7+ mouse. Lane 2, from a homozygous null mutant {alpha}7 mouse, shows no specific bands.

 
Immunohistochemistry was performed using tissue from both {alpha}7+ and {alpha}7 genotypes, with or without LPS injection. A variety of commercially available antibodies were used (Table 1). Shown in Figure 5 are three anti-{alpha}7 antibodies (mAb 319 in panels A,B; mAb 306 in panels C,D; and pAb H-302 in panels E,F). Each antibody showed intense, ubiquitous labeling of neurons throughout the brain; cortical neurons are shown in this figure. No difference in the staining patterns was seen between untreated {alpha}7+ (Panels A,C,E) and {alpha}7 mice (Panels B,D,F). All three antibodies immunolabeled neurons in both genotypes. LPS injection into the hippocampus caused reactive astrogliosis similar to that seen in Figure 3 (data not shown). Again, mAb 319 labeled astrocytes in both {alpha}7+ and {alpha}7 mice. Astrocytes were not labeled by mAb 306 or pAb H-302 in either genotype or treatment. Thus, regardless of treatment or antibody used, both {alpha}7+ and {alpha}7 mice showed distinct nonspecific labeling of neurons (mAbs 306 and 319, and pAb H-302) as well as astrocytes (mAb 319).



View larger version (105K):
[in this window]
[in a new window]
 
Figure 5

Immunohistochemical analysis of nontransgenic {alpha}7+ and null mutant {alpha}7 tissue. Horizontal sections were immunohistochemically analyzed using various anti-{alpha}7 antibodies. Micrographs show neurons in the frontal cortex. Ubiquitous staining of cell bodies was seen with all antibodies. Some cytoplasm and processes are stained with mAb 306 (C,D) (1:3000 dilution) and pAb H-302 (E,F) (1:200 dilution). mAb 319 primarily stained neuronal cell bodies and nuclei (A,B) (1:5000 dilution). Neurons in both {alpha}7+ (A,C,E) and {alpha}7 (B,D,F) tissue were immunolabeled by these anti-{alpha}7 antibodies. Bar = 50 µm.

 
Antibody staining patterns were also examined by Western blot, using cortical tissue from both genotypes, with or without LPS injection. The exposure times were increased to maximize detection of faint bands. Although most antibodies showed many nonspecific bands, no antibody revealed differences between untreated {alpha}7+ versus {alpha}7 mice at the expected molecular weight of 56 kDa (Figure 6) . LPS injection caused upregulation of an unknown protein in both {alpha}7+ and {alpha}7 mice at ~45 kDa (mAb 306) and ~75 kDa (mAb 306, pAb H-302). No additional bands were seen with mAb 319 after LPS treatment. However, none of the antibodies detected differences between LPS-treated {alpha}7+ versus {alpha}7 mice.



View larger version (41K):
[in this window]
[in a new window]
 
Figure 6

Western blot analysis of non-transgenic {alpha}7+ and null mutant {alpha}7 tissue. Cortical tissue was homogenized, subjected to SDS-PAGE, transferred, and immunoblotted. Enhanced chemiluminescence detection was captured with subsequent film exposure. The scanned image shown contains typical samples of alternating lanes of {alpha}7+ tissue and {alpha}7 tissue. Tissues from both untreated control mice and LPS-injected mice were run for each genotype and antibody. A primary band at 45 kDa and a secondary band at 30 kDa were seen with mAb 319 (lanes 1–4). Strong bands at 30, 50, and 75 kDa were seen with mAb 306 (lanes 5–8). Strong bands at 30, 45, 75, and 100 kDa were evident with pAb H-302 (lanes 9–12). Both non-transgenic {alpha}7+ and null mutant {alpha}7 tissues were immunolabeled by these anti-{alpha}7 antibodies. LPS treatment resulted in an increase in immunolabeling by mAb 306 (bands at 50 and 75 kDa) and pAb H-302 (bands at 75 kDa). This increase in staining was seen in both {alpha}7+ and {alpha}7 tissue.

 

    Discussion
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 
Three different commercially available antibodies intended to label {alpha}7 nAChR subunits were used in standard immunohistochemical and immunoblotting protocols. The antibodies were generated using different host species and different {alpha}7 subunit sequences, although all products are directed toward portions of exon 10.

Previous reports have shown the utilization of monoclonal antibodies from clones 306 and 319 for immunohistochemical analysis of rat brain (Del Toro et al. 1994Go). The results reported by Del Toro indicated ubiquitous neuronal expression, similar to that seen in our studies. Both the Del Toro procedure and ours used paraformaldehyde fixation of the brain prior to sucrose cryoprotection. Both procedures used 25-µm free-floating sections, an avidin-biotin-peroxidase protocol, and diaminobenzidine tetrahydrochloride color development. The immunohistochemical protocols used in our experiments were developed to yield significant positive stain while minimizing background. Various concentrations and combinations of primary (1:100–1:10,000) and secondary (1:1000–1:10,000) antibodies were tested in an effort to identify conditions that stained the {alpha}7+/+ mice but not the {alpha}7-null mice, without success. Tissue perfusion (saline versus paraformaldehyde) and post-fixation times (2–24 hr) were also evaluated separately in non-transgenic {alpha}7+ mice. No differences in the immunolabeling patterns were seen with any of these variations. It is conceivable that the antigenic determinant(s) was modified by the paraformaldehyde treatment (Montero, 2003Go). Another possibility is that the levels of {alpha}7 may be so low, or the amount of antibody needed to yield a signal so high, that cross-reacting protein binding masked any {alpha}7-positive cells. Other researchers who have worked with the {alpha}7-null mice did not use immunohistochemistry to demonstrate the absence of this receptor, but rather showed the absence of {alpha}-bungarotoxin binding in unfixed tissue (Orr-Urtreger et al. 1997Go; Franceschini et al. 2002Go; Wang et al. 2003Go). Using our paraformaldehyde-treated tissue, we failed to detect specific labeling using fluorophore-conjugated {alpha}-bungarotoxin (data not shown).

The immunolabeling of reactive astrocytes in amyloid-depositing mice by mAb 319 was an interesting finding of these studies. Subsequent studies with LPS injection in {alpha}7 knockout mice revealed this labeling to be nonspecific. A recent report by Teaktong et al. (2003)Go showed immunolabeled {alpha}7+ astrocytes in human AD brain. Cholinergic signaling by rat astrocytes has been demonstrated (Sharma and Vijayaraghavan, 2001Go). Activation of these cells produced calcium flux that was blocked by {alpha}-bungarotoxin, indicating the presence of {alpha}7 nAChRs. The potential for some of the astrocyte {alpha}7 labeling to be specific should not be ruled out. Thus, in designing experiments to evaluate {alpha}7 expression, an alternative approach would be the use of {alpha}-bungarotoxin instead of anti-{alpha}7 antibodies. However, we were unable to develop adequate {alpha}-bungarotoxin labeling in formaldehyde-fixed sections.

Several reports have demonstrated Western blot analysis of {alpha}7 in rodent brain extracts using monoclonal antibodies from clones 306 and 319 (Schoepfer et al. 1990Go; Del Toro et al. 1994Go; Orr-Urtreger et al. 1997Go; Dineley et al. 2001Go; Fabian-Fine et al. 2001Go). These reports have listed the apparent molecular weight of the {alpha}7 subunit as ranging from 48 to 72 kDa, although the calculated molecular weight is 56 kDa. Some of the investigators used standard homogenization procedures, SDS-PAGE separation, transfer, and subsequent immunoblotting, similar to the procedure described here. Other reports affinity purified the {alpha}7 nAChRs with cobratoxin or bungarotoxin prior to SDS-PAGE, resulting in a primary band at ~56 kDa (Del Toro et al. 1994Go; Orr-Urtreger et al. 1997Go). The immunoblotting protocols used in our laboratory were developed to minimize nonspecific bands and background. Various concentrations and combinations of primary and secondary antibodies, ranging from 1:50 to 1:10,000, were tested in an effort to come up with conditions that differentiated between the {alpha}7+ and the {alpha}7-null mice, without success. Separately, various homogenization buffers (10 mM HEPES ± 1–2% Triton X-100, 50–150 mM PBS ± 1–2% Triton X-100, 50 mM TBS ± 1–2% Triton X-100), vendors of secondary antibodies (Vector, Santa Cruz), blocking solutions (BST + 2.5–5% milk, tris buffered saline plus 0.05% tween-20 + 2.5–5% milk), and subcellular fractionation preparations (crude, membrane, and solubilized fractions) were tried, but failed to reveal differences in the staining pattern between {alpha}7+ and {alpha}7-null mice. Other researchers who have performed Western blot analysis of {alpha}7-null tissue did not use commercially available antibodies, and also affinity purified the {alpha}7 subunit before analysis (Orr-Urtreger et al. 1997Go; Franceschini et al. 2002Go; Wang et al. 2003Go). Again, an alternative approach in designing experiments to evaluate {alpha}7 expression would be the use of {alpha}-bungarotoxin affinity purification. However, the large amounts of tissue needed for affinity purification complicate the procedure and preclude analysis of small brain regions (such as the hippocampus) in individual rodents.

There have been reports of a partial duplication of the human {alpha}7 nAChR gene, which has four novel N terminus exons and conserved exons 5–10 (Gault et al. 1998Go; Villiger et al. 2002Go). Such duplication has not been reported in rodents, but cannot be completely ruled out. If there were such duplication, it might account for the {alpha}7 protein detection in the absence of {alpha}7 gene expression. Still, one would expect at least a quantitative difference in the amounts of stained material. Alternatively spliced {alpha}7 mRNAs have recently been shown in mice (Saragoza et al. 2003Go). The resultant mRNA includes a novel exon 9b. Additionally, another splice variant with novel exon 4b has been reported in rat (Severance et al. 2002Go). The Saragoza variant could potentially interfere with our RNA analysis, in as much as the primers are designed to prime to exons 9–10. In contrast, the Severance variant does contain exons 9–10 and should be eliminated in the knockout mouse. However, alternatively spliced mRNAs would have no effect on the genotyping results, because exons 8–10 are interrupted in the knockout. Moreover, the complete absence of {alpha}7 mRNA in the null mice would require some mutation in any duplicated {alpha}7 gene, which would disrupt the annealing of the primer pairs. We find such circumstances unlikely to account for the results we have obtained here.

In conclusion, careful examination of protocols is necessary when drawing conclusions from immunodetection studies of {alpha}7 nAChRs. Localization of the {alpha}7 subunit with immunohistochemistry must be interpreted with caution. Confirmation with {alpha}-bungarotoxin-binding experiments is recommended, as well as RNA analysis, where applicable.


    Acknowledgments
 
This work was supported by grants AG15490 and AG18478 from the National Institute on Aging. It was an honor to have Dr. Hannsjoerg Schroeder of the University of Cologne and Dr. Jon Lindstrom of the University of Pennsylvania provide critical comments for this manuscript, for which the authors thank them.


    Footnotes
 
Received for publication March 18, 2004; accepted May 27, 2004


    Literature Cited
 Top
 Summary
 Introduction
 Materials and Methods
 Results
 Discussion
 Literature Cited
 

Auld DS, Kornecook TJ, Bastianetto S, Quirion R (2002) Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 68:209–245[CrossRef][Medline]

Del Toro ED, Juiz JM, Peng X, Lindstrom J, Criado M (1994) Immunocytochemical localization of the {alpha}7 subunit of the nicotinic acetylcholine receptor in the rat central nervous system. J Comp Neurol 349:325–342[Medline]

DiCarlo G, Wilcock D, Henderson D, Gordon M, Morgan D (2001) Intrahippocampal LPS injections reduce Aß load in APP+PS1 transgenic mice. Neurobiol Aging 22:1007–1012[CrossRef][Medline]

Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan DG (2003) Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23:5219–5226[Abstract/Free Full Text]

Dineley K, Westerman M, Bui D, Bell K, Asche K, Sweatt D (2001) ß-Amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha 7 nicotinic acetylcholine receptors. In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21:4125–4133[Abstract/Free Full Text]

Dineley KT, Bell KA, Bui D, Sweatt JD (2002) Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem 277:25056–25061[Abstract/Free Full Text]

Fabian-Fine R, Skehel P, Errington ML, Davies HA, Sher E, Stewart MG, Fine A (2001) Ultrastructural distribution of the alpha 7 nicotinic acetylcholine receptor subunit in rat hippocampus. J Neurosci 21:7993–8003[Abstract/Free Full Text]

Franceschini D, Paylor R, Broide R, Salas R, Bassetto L, Gotti C, De Biasi M (2002) Absence of {alpha}7-containing neuronal nicotinic acetylcholine receptors does not prevent nicotine-induced seizures. Brain Res Mol Brain Res 98:29–40[Medline]

Gault J, Robinson M, Berger R, Drebing C, Logrel J, Hopkins J, Moore T, et al. (1998) Genomic organization and partial duplication of the human {alpha}7 neuronal nicotinic acetylcholine receptor gene (CHRNA7). Genomics 52:173–185[CrossRef][Medline]

Gordon MN, Holcomb LA, Jantzen PT, DiCarlo G, Wilcock D, Boyett KW, Connor K, et al. (2002) Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp Neurol 173:183–195[CrossRef][Medline]

Gordon MN, King DL, Diamond DM, Jantzen PT, Boyett KW, Hope CE, Hatcher JM, et al. (2001) Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol Aging 22:377–385[CrossRef][Medline]

Gordon MN, Schreier WA, Ou X, Holcomb LA, Morgan DG (1997) Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol 388:106–119[CrossRef][Medline]

Graham AJ, Marin-Ruiz CM, Teaktong T, Ray MA, Court JA (2002) Human brain nicotinic receptors, their distribution, and participation in neuropsychiatric disorders. Curr Drug Targets CNS Neurol Disord 1:387–397[Medline]

Grassi F, Palma E, Tonini R, Amici M, Ballivet M, Eusebi F (2003) Amyloid beta(1-42) peptide alters the gating of human and mouse alpha-bungarotoxin-sensitive nicotinic receptors. J Physiol 547:147–157[Abstract/Free Full Text]

Hauss-Wegrzyniak B, Lukovic L, Bigaud M, Stoeckel ME (1998) Brain inflammatory response induced by intracerebroventricular infusion of lipopolysaccharide: an immunohistochemical study. Brain Res 794:211–224[CrossRef][Medline]

Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, et al. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97–100[CrossRef][Medline]

Lee DH, Wang HY (2003) Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55:25–30[CrossRef][Medline]

Liu Q, Kawai H, Berg DK (2001) Beta-amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci USA 98:4734–4739[Abstract/Free Full Text]

McGehee DS, Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57:521–546[CrossRef][Medline]

Montero C (2003) The antigen-antibody reaction in immunohistochemistry. J Histochem Cytochem 51:1–4[Abstract/Free Full Text]

Orr-Urtreger A, Goldner FM, Saeki M, Lorenzo I, Goldberg L, De Biasi M, Dani JA, et al. (1997) Mice deficient in the alpha7 neuronal nicotinic acetylcholine receptor lack alpha-bungarotoxin binding sites and hippocampal fast nicotinic currents. J Neurosci 17:9165–9171[Abstract/Free Full Text]

Perry EK, Martin-Ruiz CM, Court JA (2001) Nicotinic receptor subtypes in human brain related to aging and dementia. Alcohol 24:63–68[CrossRef][Medline]

Pettit DL, Shao Z, Yakel JL (2001) Beta-amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21:RC120[Medline]

Saragoza PA, Modir JG, Goel N, French KL, Li L, Nowak MW, Stitzel JA (2003) Identification of an alternatively processed nicotinic receptor alpha7 subunit RNA in mouse brain. Brain Res Mol Brain Res 117:15–26[Medline]

Schoepfer R, Conroy WG, Whiting P, Gore M, Lindstrom J (1990) Brain alpha-bungarotoxin binding protein cDNAs and Mabs reveal subtypes of this branch of the ligand-gated ion channel gene superfamily. Neuron 5:35–48[Medline]

Seguela P, Wadiche J, Dineley-Miller K, Dani JA, Patrick JW (1993) Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J Neurosci 13:596–604[Abstract]

Severance EG, Amin JA, Hadley SH, Cuevas J (2002) Tissue distribution and functional expression of the mammalian alpha 7-2 nicotinic acetylcholine receptor subunit isoform. Society for Neuroscience Annual Meeting, New Orleans, LA

Sharma G, Vijayaraghavan S (2001) Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proc Natl Acad Sci USA 98:4148–4153[Abstract/Free Full Text]

Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, Hall R, et al. (2003) Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia 41:207–211[CrossRef][Medline]

Villiger Y, Szanto I, Jaconi S, Blanchet C, Buisson B, Krause KH, Bertrand D, et al. (2002) Expression of an {alpha}7 duplicate nicotinic receptor-related protein in human leukocytes. J Neuroimmunol 126:86–98[CrossRef][Medline]

Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, et al. (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421:384–388[Medline]

Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000a) Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275:5626–5632[Abstract/Free Full Text]

Wang HY, Lee DH, Davis C, Shank RP (2000b) Amyloid peptide AB1-42 binds selectively and with picomolar affinity to alpha 7 nicotinic acetylcholine receptors. J Neurochem 75:1155–1161[CrossRef][Medline]

Wevers A, Monteggia L, Nowacki S, Bloch W, Schutz U, Lindstrom J, Pereira EFR, et al. (1999) Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci 11:2551–2565[CrossRef][Medline]